In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway

<p>MSCs cocultured with ICT improved survival rates and hepatic function in a rat model of ALF. (a) Survival analysis of D-GalN/LPS-treated ALF rats in each group. (b) AST and ALT enzyme levels in peripheral blood samples collected at 24 h after model establishment. (c) AST and ALT enzyme levels in peripheral blood samples collected at 48 h after model establishment. <sup>∗</sup>P &lt; 0.05<i> vs. </i>the NS group; <sup>#</sup>P &lt; 0.05<i> vs. </i>the MSCs group. Data are means ± SD. Each experiment was replicated 6 times. Abbreviations. MSCs: mesenchymal stem cells; ALT: alanine aminotransferase; AST: aspartate aminotransferase.</p>

Evidence-Based Complementary and Alternative Medicine

fig1

Figure 1

Figure 1: In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway 

Figure 1 | In a Rat Model of Acute Liver Failure, Icaritin Improved the Therapeutic Effect of Mesenchymal Stem Cells by Activation of the Hepatocyte Growth Factor/c-Met Pathway 